738
Participants
Start Date
January 31, 2004
Primary Completion Date
July 31, 2005
Study Completion Date
July 31, 2005
Avelox (Moxifloxacin, BAY12-8039)
Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
Levofloxacin + Ceftriaxone
Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
Bruxelles - Brussel
Bruxelles - Brussel
Johannesburg
Leuven
Liège
Namur
Somerset West
Bloemfontein
Berlin
Athens
Berlin
Aix-en-Provence
México, D.F.
México, D.F.
Afula
Guadalajara
Brive-la-Gaillarde
Huesca
Madrid
Alcalá de Henares
Saint-Gaudens
Bordeaux
Paderborn
Magdeburg
Guadalajara
Bochum
Bochum
Kaunas
Valencia
Kaunas
Agen
Toluca
Tel Litwinsky
Holon
Lüdenscheid
Tel Aviv
Monterrey
Vesoul
Paris
Ashkelon
Toulon
Avignon
Belfort
Argenteuil
Vicente López
Buenos Aires
Buenos Aires
Buenos Aires
Buenos Aires
Temuco
Viña del Mar
Santiago
Bogotá
Bucaramanga
Bloemfontein
Cape Town
Halle
Rio
Thessaloniki
Vilnius
Vilnius
México, D.F.
México, D.F.
Eindhoven
's-Hertogenbosch
Ede
Harderwijk
Heerlen
Callao
Lima
Lima Cercado
Bydgoszcz
Gdansk
Krakow
Lodz
Warsaw
Warsaw
Wroclaw
Lisbon
Brits
Pretoria
Barcelona
Barcelona
L'Hospitalet de Llobregat
Jönköping
Kalmar
Karlstad
Skövde
Middlesbrough
Dumfries
Hull
Edinburgh
Rotherham
Sheffield
Newcastle upon Tyne
Lead Sponsor
Bayer
INDUSTRY